Long Island's push to attract biotech startups has seen mixed results. The Broad Hollow Bioscience Park, with its recent addition of a 43,000-square-foot building, aims to foster new companies. While OSI Pharmaceuticals is expanding, other firms like Helicon Therapeutics have moved away due to delays. Despite significant investment and low rent incentives, the region’s biotech sector struggles to gain traction, facing challenges such as high costs and stiff competition from established hubs.
04
Jun
